Profil
Andrew King worked as a Senior Director of Discovery & Translational Biology at Ardelyx, Inc. He then served as the Chief Scientific Officer at Chinook Therapeutics, Inc. from 2021 to 2023.
Dr. King holds a doctorate degree from Michigan State University and an undergraduate degree from Murdoch University.
Anciens postes connus de Andrew King
| Sociétés | Poste | Fin |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 09/08/2023 |
| ARDELYX, INC. | Corporate Officer/Principal | - |
Formation de Andrew King
| Murdoch University | Undergraduate Degree |
| Michigan State University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARDELYX, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
